NASDAQHealth CareDiagnostics & ResearchSnapshot 2026-07-23
Reading MYGN? Create a free portfolio, then add this holding for ongoing Reports and tracking. Track it in a free portfolio. No credit card.
Create your account →A long-form read on the 1–3 year hold thesis. Slower and deeper than the daily snapshot — it refreshes only when the evidence moves.
MYGN represents a speculative growth investment with a medium confidence level. The current thesis is intact, supported by the company's recent financial performance, but it faces significant risks and uncertainties.
The market seems to have priced in a low expectations gap, indicating that MYGN is viewed as relatively cheap compared to its peers. However, the valuation is justified given the company's loss-making status and recent earnings misses.
Fundamentals may show limited progress towards management's revenue guidance of $860M-$880M for 2026, as recent quarterly revenue has declined. The company is also facing high risk due to its history of consecutive earnings misses, which could impact future performance.
The thesis hinges on the company's ability to maintain its revenue guidance and achieve its adjusted gross margin and EBITDA targets. Additionally, the performance of sector bellwethers like TMO, DHR, and IDXX will be crucial, as their results could influence MYGN's trajectory.
Overall, MYGN's outlook remains uncertain, with several factors that could impact its performance in the coming years. Not investment advice.
The most important moves since the prior daily snapshot.
Our read on the company is unchanged since the prior snapshot.
as of 2026-07-23
Specific, dated things to watch for, each with what would confirm it and what would prove it wrong.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Why it matters: Q2 revenue will show if the company can meet its full-year guidance of $860M-$880M.
Confirms:Q2 revenue was over $210M. This shows progress toward the $860M-$880M goal.
Disproves:Q2 revenue was under $200M. This shows ongoing problems in meeting the goal.
Why it matters: EBITDA results will show if the company is on track for $37M-$49M in 2026.
Confirms:Adjusted EBITDA reported at or above $37M in Q2.
Disproves:Adjusted EBITDA was under $37M. This shows money problems.
Why it matters: Revenue guidance of $860M-$880M shows strong business trends. It also boosts investor confidence.
Confirms:Q2 revenue meets or exceeds $200.4 million, supporting full-year guidance.
Disproves:Q2 revenue is under $200 million. This shows challenges in meeting guidance.
Why it matters: This margin range shows good cost management. It helps meet profit goals.
Confirms:Adjusted gross margin reported between 68% and 69% in Q2.
Disproves:Adjusted gross margin is below 68%. This shows there are cost pressures.
